A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- 09 Jan 2019 Biomarkers information updated
- 04 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Aug 2013 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University, NSABP-B49).